|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
1993-6-14
|
|
pubmed:abstractText |
Based on prior experience with dacarbazine (DTIC) and an outpatient interleukin-2 (IL-2) regimen, the current study was conducted to improve the antitumor efficacy and assess the immunologic interactions between chemotherapy and IL-2.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
71
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3520-5
|
|
pubmed:dateRevised |
2010-3-24
|
|
pubmed:meshHeading |
pubmed-meshheading:8490900-Adolescent,
pubmed-meshheading:8490900-Adult,
pubmed-meshheading:8490900-Aged,
pubmed-meshheading:8490900-Ambulatory Care,
pubmed-meshheading:8490900-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:8490900-Cisplatin,
pubmed-meshheading:8490900-Dacarbazine,
pubmed-meshheading:8490900-Drug Administration Schedule,
pubmed-meshheading:8490900-Female,
pubmed-meshheading:8490900-Humans,
pubmed-meshheading:8490900-Infusions, Intravenous,
pubmed-meshheading:8490900-Interleukin-2,
pubmed-meshheading:8490900-Male,
pubmed-meshheading:8490900-Melanoma,
pubmed-meshheading:8490900-Middle Aged,
pubmed-meshheading:8490900-Remission Induction
|
|
pubmed:year |
1993
|
|
pubmed:articleTitle |
A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanoma.
|
|
pubmed:affiliation |
Department of Internal Medicine, Wayne State University School of Medicine, Detroit, Michigan.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase II
|
